‘Pent-up demand’ for FDA-approved cannabis drug boosts UK maker

Strong patient interest in the only federally approved CBD product in the United States helped drugmaker GW Pharmaceuticals record $72 million in revenue last quarter. Epidiolex, which is made by London’s GW Pharma (Nasdaq: GWPH), is a seizure control drug approved by the U.S. Food and Drug Administration. It has seen brisk sales and new patient enrollments since the […]

‘Pent-up demand’ for FDA-approved cannabis drug boosts UK maker is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs